Phase 1 Leukemia clinical trials

106 recruiting Phase 1 leukemia studies in the US. What trial phases mean

Other phases

RecruitingPhase 1NCT06575296

Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant

Sponsor: City of Hope Medical Center

Duarte, CA

RecruitingPhase 1NCT06904066

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Sponsor: National Cancer Institute (NCI)

Bethesda, MD

RecruitingPhase 1NCT06846606

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

Sponsor: Auron Therapeutics, Inc.

Duarte, CA · Tampa, FL · Buffalo, NY · +6 more sites

RecruitingPhase 1NCT04301076

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

Sponsor: National Cancer Institute (NCI)

Atlanta, GA · City of Saint Peters, MO · +16 more sites

RecruitingPhase 1NCT06528301

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Sponsor: Umoja Biopharma

Duarte, CA · Chicago, IL · Grand Rapids, MI · +4 more sites

RecruitingPhase 1NCT07424833

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

Sponsor: Ascentage Pharma Group Inc.

Los Angeles, CA · Jacksonville, FL · Grand Rapids, MI · +2 more sites

RecruitingPhase 1NCT07532525

Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma

Sponsor: University of Michigan Rogel Cancer Center

Ann Arbor, MI

RecruitingPhase 1NCT07723703

Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML

Sponsor: Amphista Therapeutics Ltd

Fairfax, VA

RecruitingPhase 1NCT05188170

Niclosamide in Pediatric Patients With Relapsed and Refractory AML

Sponsor: Stanford University

Palo Alto, CA

RecruitingPhase 1NCT02390635

PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 1NCT05010772

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 1NCT07388563

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

Sponsor: National Cancer Institute (NCI)

Bethesda, MD

RecruitingPhase 1NCT07751991

A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML

Sponsor: Charm Therapeutics

Duarte, CA · New Haven, CT · Grand Rapids, MI

RecruitingPhase 1NCT03896269

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 1NCT05091424

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Sponsor: Hoffmann-La Roche

Rochester, MN · New York, NY · Columbus, OH · +2 more sites

RecruitingPhase 1NCT06440135

Ziftomenib Maintenance Post Allo-HCT

Sponsor: Massachusetts General Hospital

Boston, MA · Columbus, OH

RecruitingPhase 1NCT07306832

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Sponsor: AbbVie

Palo Alto, CA · Atlanta, GA · Valhalla, NY · +2 more sites

RecruitingPhase 1NCT07548983

Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation

Sponsor: OHSU Knight Cancer Institute

Portland, OR

RecruitingPhase 1NCT03802695

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Sponsor: Orca Biosystems, Inc.

Duarte, CA · Sacramento, CA · Stanford, CA · +9 more sites

RecruitingPhase 1NCT06401603

A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 1NCT07661095

A Study of CRD3874-SI in People With Leukemia

Sponsor: Memorial Sloan Kettering Cancer Center

Basking Ridge, NJ · Middletown, NJ · Montvale, NJ · +4 more sites

RecruitingPhase 1NCT03630991

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 1NCT04375631

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Sponsor: Fred Hutchinson Cancer Center

Seattle, WA

RecruitingPhase 1NCT06786533

Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML

Sponsor: Hemogenyx Pharmaceuticals LLC

Houston, TX

RecruitingPhase 1NCT06345027

Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)

Sponsor: Baylor College of Medicine

Houston, TX

RecruitingPhase 1NCT06735664

Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation

Sponsor: City of Hope Medical Center

Duarte, CA

RecruitingPhase 1NCT06810583

A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia

Sponsor: St. Jude Children's Research Hospital

Memphis, TN

RecruitingPhase 1NCT04972942

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma

Sponsor: New York Medical College

Phoeniz, AZ · Loma Linda, CA · Los Angeles, CA · +13 more sites

RecruitingPhase 1NCT05010005

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Sponsor: Memorial Sloan Kettering Cancer Center

Miami, FL · Boston, MA · Basking Ridge, NJ · +6 more sites

RecruitingPhase 1NCT07225439

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Sponsor: Paolo Caimi, MD

Cleveland, OH

RecruitingPhase 1NCT03666000

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Sponsor: Imugene Limited

Tampa, FL · Atlanta, GA · +7 more sites

RecruitingPhase 1NCT05010564

Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)

Sponsor: Baylor College of Medicine

Houston, TX

RecruitingPhase 1NCT06397027

A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 1NCT07347418

CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML

Sponsor: University of Colorado, Denver

Aurora, CO

RecruitingPhase 1NCT06408194

Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

Sponsor: Stanford University

Palo Alto, CA

RecruitingPhase 1NCT07025564

MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Sponsor: City of Hope Medical Center

Duarte, CA

RecruitingPhase 1NCT04881240

Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia

Sponsor: St. Jude Children's Research Hospital

Memphis, TN

RecruitingPhase 1NCT07177079

High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)

Sponsor: Kittika Poonsombudlert

Iowa City, IA

RecruitingPhase 1NCT07257419

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

Sponsor: St. Jude Children's Research Hospital

Memphis, TN

RecruitingPhase 1NCT05857969

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

Sponsor: Florida International University

Miami, FL

RecruitingPhase 1NCT06227026

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies

Sponsor: University of Utah

Salt Lake City, UT

RecruitingPhase 1NCT07439211

Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia

Sponsor: Jacqueline Garcia, MD

Boston, MA

RecruitingPhase 1NCT06247787

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Sponsor: Children's Oncology Group

Birmingham, AL · Orange, CA · San Francisco, CA · +16 more sites

RecruitingPhase 1NCT07573111

Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation

Sponsor: Laguna Biotherapeutics, Inc.

Palo Alto, CA

RecruitingPhase 1NCT06001788

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Sponsor: Kura Oncology, Inc.

Gilbert, AZ · Los Angeles, CA · +35 more sites

RecruitingPhase 1NCT02203903

Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies

Sponsor: Catherine Bollard

Washington D.C., DC · Baltimore, MD

RecruitingPhase 1NCT07513129

Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 1NCT05887167

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

Sponsor: Joshua Sasine, MD, PhD

Los Angeles, CA

RecruitingPhase 1NCT06285890

Phase I Study of HC-7366 for Acute Myeloid Leukemia

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 1NCT07250646

A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis

Sponsor: Aspera Biomedicines, Inc.

Duarte, CA · Sacramento, CA · San Diego, CA

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.